Author

Edith Arely Lemus-Carmona

Observed names: E Lemus-Carmona, E. Lemus-Carmona, E.A. Lemus, E.A. Lemus-Carmona, E.A. Lemus-carmona, EA Lemus-Carmona, Edith A. Lemus-Carmona, Edith Arely Lemus Carmona, Edith Lemus

Observed institutions: Novartis (Mexico), Sanofi (Mexico)

OpenAlex ID: A5038720341

Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis

2013 · Miguel A. Macías-Islas, Isaac F. Soria-Cedillo, et al. · Acta Neurologica Belgica · 10

The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.

2005 · Armando Arredondo, Thomas A Burke, et al. · PubMed · 5

Economic Impact Of Rheumatic Diseases In Mexico

2014 · H Arreola-Ornelas, LM Camacho-Cordero, et al. · Value in Health · 4

[Private expenditure in health by state in Mexico].

2005 · Sergio Sesma-Vázquez, Raymundo Pérez-Rico, et al. · PubMed · 2

Direct Cost of Myelodysplastic Syndromes Associated With A Deletion 5q Cytogenetic Abnormality (Del5q Mds) In Patients Who Are Red Blood Cell Transfusion Dependent In Mexico

2015 · A Reyes-Lopez, F Lemus-Villafuerte, et al. · Value in Health · 1

PDF

Cost-effectiveness of drug treatment of systemic hypertension

2009 · José Z. Parra-Carrillo, Juan Verdejo-París, et al. · Cardiovascular and Metabolic Science · 1

Economic Evaluation of Lenalidomide in the Treatment of Lower Risk Myelodysplastic Syndromes With Del5q (mds Del5q) in Mexico

2016 · C. Ramos, E. Montaño, et al. · Value in Health

Análisis Descriptivo del Cuadro Básico y Catálogo de Medicamentos en México

2014 · Romay Márquez Sánchez, Edith Arely Lemus Carmona, et al. · Memorias del Concurso Lasallista de Investigación Desarrollo e innovación

RETRACTED: Evaluación económica de ranibizumab en pacientes adultos con degeneración macular relacionada con la edad (DMRE) exudativa en México

2014 · Héctor Arreola-Ornelas, Edith Arely Lemus-Carmona, et al. · Revista Mexicana de Oftalmología

Clinical Benefits of Immunosuppression Therapy in Renal Trasplant Patients. Systematic Review and Meta-Analysis

2013 · O. Cerezo, M.G. Bravo, et al. · Value in Health

Análisis del costo-efectividad del indacaterol una vez al día como terapia broncodilatadora de mantenimiento en pacientes con EPOC en México: análisis a largo plazo

2013 · Alfonso Reyes López, Edith Arely Lemus-Carmona, et al. · Anales Médicos de la Asociación Médica del Centro Médico ABC

PRS25 Cost Analysis of Omalizumab Use in Patients With Severe Uncontrolled Asthma Within the Mexican Public Health Care System

2012 · E. Lemus-Carmona, A. Reyes-Lopez, et al. · Value in Health

PSS10 Cost- Effectiveness of Ranibizumab in Patients with Neovascular Wet Age-Related Macular Degeneration (Namd) at the Mexican Social Security System (Imss)

2012 · H. Arreola-Ornelas, A. Rosado-Buzzo, et al. · Value in Health

PRS22 Cost-Effectiveness of Indacaterol on Patients with Chronic Obstructive Pulmonary Disease (Copd) at the Public Mexican Health Care System

2012 · A. Reyes-lopez, E.A. Lemus-carmona, et al. · Value in Health

PND18 Cost- Effectiveness of Fingolimod on Patients With Multiple Sclerosis at the Public Mexican Health Care System

2012 · I.F. Soria-Cedillo, V. Baca-Muro, et al. · Value in Health

PDF

Works count: 15

Citation count: 23

H-index: 3

I10-index: 1